 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| perenostobart (SRF617) / Coherus Biosci
Trial termination, Combination therapy, Metastases: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 20, 2024
P2, N=16, Terminated, Sponsor: Coherus Biosciences, Inc.
Completed --> Terminated; The study was terminated for strategic reasons, not due to any safety concerns.
- ||| perenostobart (SRF617) / Coherus Biosci
Trial completion, Enrollment change, Metastases: KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 28, 2023
P1, N=85, Completed, Sponsor: Surface Oncology
Completed --> Terminated; The study was terminated for strategic reasons, not due to any safety concerns. Active, not recruiting --> Completed | N=177 --> 85
- | SRF617 / Surface Oncology
Journal, Immunomodulating: SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties. (Pubmed Central) - May 27, 2023
Active, not recruiting --> Completed | N=177 --> 85 Syngeneic tumor studies using human CD39 knock-in mice show that SRF617 can modulate CD39 levels on immune cells in
- ||| perenostobart (SRF617) / Coherus Biosci
Trial completion, Enrollment change, Combination therapy, Metastases: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 12, 2023
P2, N=15, Completed, Sponsor: Surface Oncology
Syngeneic tumor studies using human CD39 knock-in mice show that SRF617 can modulate CD39 levels on immune cells in Active, not recruiting --> Completed | N=40 --> 15
- | perenostobart (SRF617) / Coherus Biosci
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Nov 30, 2022
P2, N=40, Active, not recruiting, Sponsor: Surface Oncology
Active, not recruiting --> Completed | N=40 --> 15 Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023
- || perenostobart (SRF617) / Coherus Biosci
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 30, 2022
P1, N=177, Active, not recruiting, Sponsor: Surface Oncology
Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023 Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Aug 2023
- ||| SRF617 / Surface Oncology
Ah, here we go. SRF617 at #Esmo21. Could explain $SURF's decision to halt! (Twitter) - Nov 2, 2022
- | SRF617 / Surface Oncology, TTX-030 / AbbVie, Trishula Therap, IPH5201 / AstraZeneca, Innate
$SURF "pausing" development of SRF617 (anti-CD39 MAb), relevant for Tizona $ABBV (TTX-030), $IPH $AZN (IPH5201) & $GILD $RCUS (AB598) (Twitter) - Nov 2, 2022
- || SRF617 / Surface Oncology
$SURF update on SRF617, a fully human antibody designed to inhibit CD39 in 2H'22. Raised $21M in Q1 via ATM. Cash, cash equivalents $150M (Twitter) - May 9, 2022
- || perenostobart (SRF617) / Coherus Biosci
Enrollment open, Combination therapy, Metastases: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 31, 2022
P2, N=40, Recruiting, Sponsor: Surface Oncology
Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Aug 2023 Not yet recruiting --> Recruiting
- || perenostobart (SRF617) / Coherus Biosci
Enrollment change, Metastases: KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 21, 2022
P1, N=177, Recruiting, Sponsor: Surface Oncology
Not yet recruiting --> Recruiting N=100 --> 177
- || perenostobart (SRF617) / Coherus Biosci
New P2 trial, Combination therapy, Metastases: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 4, 2022
P2, N=40, Not yet recruiting, Sponsor: Surface Oncology
- SRF617 / Surface Oncology
First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. (Foyer ABC [VIRTUAL]) - Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_265;
P1
Methods Pts with advanced solid tumors were enrolled in a phase 1 dose-escalation study of SRF617 (NCT04336098) to establish preliminary safety as monotherapy as well as in combination with gemcitabine + nab-paclitaxel (GA) or pembrolizumab (P) and to identify doses suitable for monotherapy and combination expansion cohorts...Legal entity responsible for the study Surface Oncology, Cambridge, MA, USA. Funding Surface Oncology, Cambridge, MA, USA.
- SRF617 / Surface Oncology
The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_330;
P1
These studies demonstrate the therapeutic potential of targeting CD39 for the treatment of cancer. SRF617 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors (NCT04336098) and in combination with chemotherapy in patients with pancreatic cancer.
- || perenostobart (SRF617) / Coherus Biosci
Enrollment change, Metastases: KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 19, 2020
P1, N=100, Recruiting, Sponsor: Surface Oncology
SRF617 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors (NCT04336098) and in combination with chemotherapy in patients with pancreatic cancer. N=56 --> 100
- SRF617 / Surface Oncology
SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2726;
Inhibition of CD39 potentiates the activity of chemotherapy and immunotherapy agents to improve tumor growth inhibition and survival in mice. These findings support future clinical studies of SRF617 as monotherapy and in combination with other therapeutic agents in treating patients with cancer.
- ||| perenostobart (SRF617) / Coherus Biosci
New P1 trial, Metastases: KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 6, 2020
P1, N=56, Recruiting, Sponsor: Surface Oncology